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ROLE OF BONE IN THE DEVELOPMENT AND
PROGRESSION OF OSTEOARTHRITIS
D. Lajeunesse
CRCHUM, Hôpital Notre-Dame, Montréal, QC, Canada
Purpose: Altered bone remodeling is now considered important in
the progression and/or initiation of osteoarthritis (OA) both from in
vivo and in vitro studies. The mechanisms that lead to altered bone
remodeling are still largely unknown yet recent studies have keyed
into the mechanisms that may be at play. Altered bone remodeling
in OA may be due to the abnormal phenotype and proliferation of
human OA osteoblasts (Ob). It may also be linked with abnormal
signaling of key growth factors that modulate both the proliferation
and function of Ob. Recent studies using imaging techniques have
also revealed new data on the possible link between bone and
lipid metabolism that may impact on OA bone tissue. The present
presentation will examine the hypothesis of the key role played by
bone in OA initiation/progression.
Methods: Many studies have demonstrated that the subchondral
bone is the site of several dynamic morphological changes that
vary over time during the evoluton of the disease and seem to be
part of the disease process. Here, we reviewed the evidence that
bone tissue and function may be affected prior to the onset of car-
tilage degradation in OA individuals. Studies aiming at deﬁning the
role of bone marrow lesions/oedema, of altered lipid metabolism,
and of identifying early biomarkers will be presented. Evidence
from microarray studies of bone tissues and in vitro experiments
with OA Ob will underline the role of speciﬁc growth factors in OA.
Results: Individuals with OA show increases in bone mass at all
sites, not just those affected by OA, and they also show increases
in body mass indes (BMI). Indeed, obesity is linked with OA,
however, biomechanical effects cannot alone explain this link and
systemic factors may be at play. Magnetic Resonance Imaging
(MRI) now shows that bone marrow lesions/oedema can be ob-
served in individuals free of OA prior to initiation of the disease
and data reveal a link between bone marrow lesions/oedema and
lipid metabolism. Abnormal bone marrow and/or bone metabolism
could be linked with an abnormal response of Ob to local and/or
systemic factors, and especially with an abnormal response to
growth factors such as insulin-like growth factor-1 (IGF-1), trans-
forming growth factor β-1 (TGF-β1), and the Wingless/β-catenin
signaling (Wnts). The abnormal response to these factors by OA
Ob inﬂuences the proliferation, differentiation and mineralization
of these cells, possibly explaining the observed sclerosis of OA
bone tissue. Moreover, factors released by OA Ob can inﬂuence
osteoblasts as well as chondrocytes. Last, efforts to determine
biomarkers of OA have now uncovered clusters of bone biomark-
ers, as well as cartilage biomarkers, that may predict early OA.
Conclusions: These results suggest that altered IGF-1, TGF-β1
and Wnt/β-catenin signaling all contribute to abnormal function of
OA Ob and are possibly linked to OA pathophysiology. Moreover,
altered lipid metabolism may lead to key alterations of bone
marrow and thereof to bone tissue and cartilage. Finally, key
bone-derived biomarkers, organized into clusters as opposed to
single biomarkers, can predict future OA onset in otherwise healthy
patients. Hence, these data strongly support a key role for altered
bone tissue remodeling in both the initiation and progression of
OA.
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PAIN INTERFERENCES ON SLEEP IN OA PATIENTS: AN
OVERVIEW
G. Lavigne
Faculte medecine dentaire, U. Montreal and Sacre Coeur
Hopsital, Montreal, QC, Canada
Purpose: Chronic pain, due to its persistent harassment effect
on the nervous and immune systems, is most likely associated
with central sensitisation, i.e., intense pain is perceived as the
result of alteration to the level of spinal and brainstem cellular
networks. Sleep is under the control of brainstem, thalamic and
hypothalamic networks. Sleep is a state of lower pain perception
that can become very instable in presence of too much interference
such as noise, pain, etc (Lavigne, Pain 2000, 2004). Active during
wake and pain states, serotonin and noradrenalin neurons are
less active during non-REM sleep and nearly silent during REM
sleep.
This is an OVERVIEW presentation - following sections were ﬁt for
requirements of Abst submission
Methods: The sleep of pain patients is characterized by high
levels of recurrent brief arousals (3-15 second rises in brain with
alpha EEG activity, motor and autonomic-cardiac activity) that
result in fragmented sleep architecture and are the source of
non-restorative sleep complaints (i.e., un-refreshing sensation).
50 to 70 % of musculoskeletal chronic pain patients report non-
restorative sleep related complaints. The presence of restorative
sleep seems to predict the resolution of chronic widespread pain
(CWP; Davies, Rheumatol 2008).
A circular model has been proposed to help explain the interaction
between pain and sleep: a night with poor sleep can be followed
by a day with more intense and variable pain, and a day with
pain can be followed by non-restorative sleep. This model is
inﬂuenced by the patient’s life style, low level of physical ﬁtness,
presence of mild (i.e., sub-threshold for diagnosis and treatment)
sleep breathing disorders (e.g., apnea/hypopnea; upper airway
resistance) or periodic limb movements (PLM).
Results: In normal and young subjects, sleep deprivation (4 hours
instead of 8 hours) triggers mood alterations and complaints
of pain after 3-4 days (Haack and Mullington, Pain 2005). In
normal subjects, deprivation of sleep stages 3&4 and REM sleep
enhances pain by reducing pain threshold or tolerance (Roehrs,
Sleep 2006; Onen, J Sleep Res 2001).
The duration of night sleep in most musculoskeletal CWP patients
is about 60 minutes less (under 6 hours per night) than that of
normal subjects (Okura, Sleep Med 2008; Edwards, Pain 2008).
Female patients with CWP present twice as many sleep awak-
enings, 25% present less REM sleep duration and 40% lower
slow wave power density during sleep. Female CWP patients also
spend 2.6 less time in sleep stages 3&4 than CWP male patients.
In patients with rheumatoid arthritis (RA), sleep duration is in the
same range to the one of control subjects (Drewes 1988). Similarly
to CWP patients, the presence of intermediate frequency of PLM
(about 10 per hr of sleep in RA; control about 1-3 and PLM pa-
tients over 20) suggest that sleep fragmentation (with arousal and
then Alpha EEG intrusions) may contribute to poor sleep quality
perception and sleep instability (Drewes 1988, Okura 2008).
Conclusions: The mode of action of medications known to im-
prove both pain and sleep complaints (i.e., pregabalin and sodium
oxybate in CWP and extended release of opioid or tramadol in
OA patients) remains to be described (i.e., speciﬁc effect on sleep
arousal-instability or continuity or circadian-homeostatic regulation
or mood -sleep interferences).
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